According to Perrigo's latest financial reports the company's current EPS (TTM) is -$0.50. In 2022 the company made an earnings per share (EPS) of -$1.04 a decrease over its 2021 EPS that were of -$0.51.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.50 | -51.92% |
2022 | -$1.04 | 103.92% |
2021 | -$0.51 | -57.5% |
2020 | -$1.20 | -211.11% |
2019 | $1.08 | 16.13% |
2018 | $0.93 | 12.05% |
2017 | $0.83 | -103.29% |
2016 | -$25.24 | 10416.67% |
2015 | -$0.24 | -108.14% |
2014 | $2.95 | 6.88% |
2013 | $2.76 | -41.77% |
2012 | $4.74 | 27.76% |
2011 | $3.71 | 23.26% |
2010 | $3.01 | 43.33% |
2009 | $2.10 | 48.94% |
2008 | $1.41 | 24.78% |
2007 | $1.13 | 46.75% |
2006 | $0.77 | -117.11% |
2005 | -$4.50 | -635.71% |
2004 | $0.84 | -20% |
2003 | $1.05 | 36.36% |
2002 | $0.77 | 35.09% |
2001 | $0.57 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
United Therapeutics UTHR | $19.32 | -3,964.00% | ๐บ๐ธ USA |
Endo International
ENDPQ | -$4.02 | 704.00% | ๐ฎ๐ช Ireland |
Intercept Pharmaceuticals
ICPT | $6.39 | -1,378.00% | ๐บ๐ธ USA |
Catalent CTLT | -$1.29 | 158.00% | ๐บ๐ธ USA |